Characterization of the attenuating M and NP gene segments of the avian influenza A/Mallard/78 virus during in vitro production of avian-human reassortant vaccine viruses and after replication in humans and primates.
A unique requirement for live attenuated reassortant influenza vaccines is the need to generate new reassortant vaccine viruses with the appearance of each new antigenic variant. Thus, the attenuation phenotype conferred by the attenuated donor influenza virus must remain genetically stable during the generation of each new reassortant vaccine virus. In this study we used nucleotide sequence analysis to evaluate the genetic stability of the attenuating M and NP genes of the avian influenza A/Mallard/NY/6750/78 attenuated donor virus during the in vitro generation and subsequent in vivo replication of avian-human (AH) influenza A reassortant vaccine viruses in monkeys and humans. Nucleotide sequence changes in the M and NP genes occurred at a rate of approximately 0.61 substitutions/1000 nt/reassortant during in vitro generation of four AH reassortant viruses. Only two nucleotide sequence changes occurred in the M and NP gene segments of four isolates of H1N1 or H3N2 AH vaccine viruses following 6-8 days of replication in seronegative children, and neither change affected amino acids previously identified as playing a potential role in attenuation. In addition, there were no changes in the nucleotide sequence of the M and NP genes of single gene AH reassortant viruses following five serial passages in squirrel monkeys. Finally, there was no change in the level or duration of replication of the single gene reassortant viruses in the upper or lower respiratory tract of monkeys following serial passage.(ABSTRACT TRUNCATED AT 250 WORDS)
Treanor
J J
JJ
Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD.
Tierney
E L
EL
London
W T
WT
Murphy
B R
BR
D000818:Animals; D001483:Base Sequence; D003001:Cloning, Molecular; D006801:Humans; D009980:Influenza A virus / Q000235:genetics* / Q000472:pathogenicity / Q000502:physiology; D007252:Influenza Vaccines / Q000235:genetics*; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins; D016133:Polymerase Chain Reaction; D011995:Recombination, Genetic / Q000502:physiology; D012453:Saimiri; D014613:Vaccines, Attenuated / Q000235:genetics; D014614:Vaccines, Synthetic / Q000235:genetics; D014758:Viral Core Proteins / Q000235:genetics*; D014763:Viral Matrix Proteins / Q000235:genetics*; D014779:Virus Replication / Q000235:genetics
D007252:Influenza Vaccines; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014758:Viral Core Proteins; D014763:Viral Matrix Proteins